ANI Pharmaceuticals Reports 43.8% Revenue Growth and Profitability Turnaround in Fiscal Year 2025

ANI Pharmaceuticals Reports Increased Revenue and Profitability in Fiscal Year 2025

ANI Pharmaceuticals, Inc. (ANI) reported a net revenue of $883.4 million for the year ended December 31, 2025, a 43.8% increase compared to $614.4 million in 2024. The company's net income reached $78.3 million, a significant turnaround from a net loss of $18.5 million in the previous fiscal year. This growth was primarily driven by increased sales in the Rare Disease and Brands segment, particularly with Purified Cortrophin Gel, which saw a 75.6% increase in revenue, and the inclusion of ILUVIEN and YUTIQ revenues following the acquisition of Alimera Sciences, Inc.

The company's Rare Disease and Brands segment experienced substantial growth, with revenues increasing by 64.4% to $484.0 million. Generic pharmaceutical product revenues also contributed to the overall growth, increasing by 27.6% to $384.1 million, driven by new product launches and increased volumes from existing products. However, royalties and other pharmaceutical services revenues decreased by 19.6% to $15.3 million. Cost of sales, excluding depreciation and amortization, increased by 36.4% to $341.3 million, but decreased as a percentage of net revenues from 40.7% to 38.6%, primarily due to the non-recurrence of inventory step-up costs related to the Alimera acquisition.

ANI Pharmaceuticals strategically expanded its Rare Disease business through the acquisition of Alimera, adding ILUVIEN and YUTIQ to its product portfolio. The company also transitioned promotional efforts in the U.S. to focus on ILUVIEN, following FDA approval of an expanded label to include treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. Furthermore, the company plans to build a dedicated sales organization focused on acute gouty arthritis flares for Cortrophin Gel in 2026. As of January 2026, ANI Pharmaceuticals employed 970 individuals across multiple locations, including the U.S., India, the UK, and Germany.

Looking ahead, ANI Pharmaceuticals aims to strengthen its Generics and Other segment through continued investment in research and development, with a focus on niche opportunities such as injectables and competitive generic therapy filings. The company expects to launch approximately 10 to 15 new products per year. ANI also intends to expand its Rare Disease and Brands offerings through organic growth and strategic acquisitions, while continuing to evaluate potential acquisitions and other strategic transactions that complement its existing portfolio and capabilities. The company's objective is to build a sustainable and growing biopharmaceutical company, serving patients in need and creating long-term value for its investors.